Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $216.00 at

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective lifted by research analysts at Oppenheimer from $200.00 to $216.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 53.51% from the stock’s previous close. […]

Related Keywords

New York , United States , Neurocrine Biosciences , Ingrid Delaet , Eric Benevich , Neurocrine Biosciences Company Profile , Goldman Sachs Group , Cantor Fitzgerald , Securities Exchange Commission , Fintrust Capital Advisors , Neurocrine Biosciences Inc , Nasdaq , Bluepath Capital Management , Wells Fargo Company , Asset Management One Co , Get Free Report , Exchange Commission , Management One , Trust Capital Advisors , York State Teachers Retirement System , Neurocrine Biosciences Daily , Nasdaq Nbix , Nbix , Medical , 64125c10 , Boost Price Target , Oppenheimer Holdings Inc ,